Biosimilar Pricing: Sandoz Vows Not To Make Omnitrope ‘Mistake’ With Filgrastim

Sandoz, Hospira execs say U.S. payers and consumers will ‘not be disappointed’ in cost savings from products approved under the 351(k) pathway, but warn that price alone may not tell whole story.